How do analysts rate BIOLINERX LTD-SPONS ADR (BLRX)?
The consensus rating for BIOLINERX LTD-SPONS ADR (BLRX) is 100 / 100 . This indicates that analysts generally have a positive outlook on the stock.
BIOLINERX LTD-SPONS ADR (BLRX) Forecast, Price Target & Analyst Ratings
NASDAQ:BLRX • US09071M2052
Current stock price
2.4 USD
+0.02 (+0.84%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOLINERX LTD-SPONS ADR (BLRX).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $2.40 to mean target of N/A, Based on 2 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
100.00%
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-30 | Jones Trading | Upgrade | Hold -> Buy |
| 2025-05-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-02 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-04 | Jones Trading | Initiate | Buy |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-25 | Oppenheimer | Reiterate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | ||
|---|---|---|---|---|
| Revenue YoY % growth | 4.8M | 28.94M 502.92% | ||
| EBITDA YoY % growth | -28.503M -18.40% | -41.607M -45.97% | -15.333M 63.15% | |
| EBIT YoY % growth | -29.157M -17.68% | -42.991M -47.45% | -19.398M 54.88% | |
| Operating Margin | N/A | -895.65% | -67.03% | |
| EPS YoY % growth | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A